Back to Journals » Cancer Management and Research » Volume 11

Imaging-Based Individualized Response Prediction Of Carbon Ion Radiotherapy For Prostate Cancer Patients

Authors Wu S, Jiao Y, Zhang Y, Ren X, Li P, Yu Q, Zhang Q, Wang Q, Fu S

Received 30 April 2019

Accepted for publication 16 September 2019

Published 24 October 2019 Volume 2019:11 Pages 9121—9131

DOI https://doi.org/10.2147/CMAR.S214020

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Melinda Thomas

Peer reviewer comments 2

Editor who approved publication: Dr Beicheng Sun


Shuang Wu,1,2,* Yining Jiao,3,* Yafang Zhang,1,2 Xuhua Ren,3 Ping Li,2,4 Qi Yu,1,2 Qing Zhang,2,4 Qian Wang,3 Shen Fu1,2,5,6

1Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China; 2Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, People’s Republic of China; 3Institute for Medical Imaging Technology, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 4Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China; 5Key Laboratory of Nuclear Physics and Ion-beam Application MOE, Fudan University, Shanghai, People’s Republic of China; 6Department of Radiation Oncology, Shanghai Concord Cancer Hospital, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Shen Fu
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, No. 4365 Kang Xin Road, Shanghai 201321, People’s Republic of China
Email shen_fu@hotmail.com
Qian Wang
Institute for Medical Imaging Technology, School of Biomedical Engineering, Shanghai Jiao Tong University, No. 1954 Hua Shan Road, Shanghai 200030, People’s Republic of China
Email wang.qian@sjtu.edu.cn

Purpose: To explore the value of the pre-treatment MRI radiomic features in individualized prediction of the therapeutic response of carbon ion radiotherapy (CIRT) for prostate cancer patients.
Patients and methods: Twenty-three patients with localized prostate cancer treated by CIRT were enrolled for analysis. Prostate tumors were manually delineated on T2-weighted (T2w) images and apparent diffusion coefficient (ADC) maps acquired before CIRT. Abundant radiomic features were extracted from the delineations, which were randomly deformed to account for delineation uncertainty. The robust features were selected and then compared between patient groups of different CIRT responses. Support vector machine (SVM) was subsequently applied to demonstrate the role of the radiomic features to predict individualized CIRT response in the way of artificial intelligence.
Results: Radiomic features from ADC had significantly higher intra-correlation coefficient (ICC) (0.71±0.28) than T2w features (0.60±0.31) (p<0.01), indicating higher robustness of ADC features against delineation uncertainty. More features were excellently robust in ADC (58.2% of all the radiomic feature candidates, compared to 41.3% in T2w). By combining the excellently robust radiomic features of T2w and ADC, SVM achieved high performance to predict individualized therapeutic response of CIRT, ie, area-under-curve (AUC) = 0.88.
Conclusion: Radiomic features extracted from T2w and ADC images displayed great robustness to quantify the tumor characteristics of prostate cancer and high accuracy to predict the individualized therapeutic response of CIRT. After further validation, the selected radiomic features may become potential imaging biomarkers in the management of prostate cancer through CIRT.

Keywords: radiomics, MRI, carbon ion radiotherapy, prostate cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]